Blend Insurance Solutions has appointed Melanie Hoffmann as head of accident and health (A&H) in Australia, as the Kaibridge-owned underwriting agency rolls out an AI-focused operating model and prepares to extend its product footprint into additional commercial classes. Hoffmann, who has more than two decades of experience in underwriting and broking, will lead Blend’s A&H division as the first line to transition to the agency’s new technology platform. Her role includes responsibility for product development, broker engagement, and the integration of accident and health offerings into a workflow built around AI-enabled processes.
Blend is restructuring its workflows to build what it describes as an AI-native ecosystem for underwriting and policy administration. A&H will be the initial test bed for this model, ahead of a planned move into further commercial classes from early 2027. Blend CEO Grant Cairns said the appointment is intended to connect underwriting leadership with the firm’s technology program. “Mel brings the depth and the relationships. By removing the technical barriers that usually get in an underwriter’s way, we’re giving her the platform to deliver exactly what brokers deserve: fast, precise, and bespoke solutions,” Cairns said.
Under Blend’s roadmap, Australian A&H products will be the first to go live on the new platform. The design is expected to provide the template for future commercial lines, shaping how risks are submitted, assessed, and quoted in the intermediated market. Hoffmann said the shift reflects broader changes in how insurance operations are organised. “The industry is at a turning point as technology unlocks smarter ways to work. Blend is acting as the pilot for a genuinely different, AI-native approach. I’m here to take that vision further and deliver the responsive results the market has been waiting for,” Hoffmann said. Kaibridge acquired Blend to act as the pilot business for its technology and operating environment and has outlined a strategy of organic expansion into new commercial lines alongside potential acquisition-led growth. The group has stated that it aims to offer brokers and their clients faster responses and underwriting and claims service in the Australian market.
Bupa has appointed Dr Michael Walsh (pictured) to the Bupa Australia and New Zealand board, effective April 1, 2026. The change comes as health insurers continue to operate within evolving policy, cost, and demographic settings across the Australian and New Zealand markets. Walsh has more than 30 years of leadership and clinical experience across Australia and the Middle East, covering major hospital operations, clinical practice, and health system reform. Most recently, he completed a five-year term as chief executive officer of Johns Hopkins Aramco Healthcare in Saudi Arabia, a joint venture between Johns Hopkins International and Aramco, before returning to Australia. Prior to that, he served as CEO of Cabrini Hospital in Melbourne for 11 years and earlier led Alfred Health as CEO for seven years.
Walsh’s public-sector experience includes executive roles with the Western Australian Department of Health, including medical director at Fremantle Hospital, and senior leadership positions within Victoria’s Department of Health, where he supported the introduction of case mix funding. Internationally, he has held leadership roles with the UK National Health Service in the South East London Strategic Health Authority and has also worked in Qatar. He holds a Master of Public Administration from Harvard University. Bupa ANZ chairman Tony Johnson said Walsh’s appointment is expected to contribute to the board’s oversight of the group’s strategy in the region. “We are incredibly fortunate to have a director of Michael’s clinical experience and leadership calibre join the Bupa ANZ board and know he will have a significant impact as we continue to support delivery of Bupa’s strategic ambitions across the region,” Johnson said.
